Literature DB >> 18180149

European surveillance study on antimicrobial susceptibility of Gram-positive anaerobic cocci.

J Brazier1, D Chmelar, L Dubreuil, G Feierl, M Hedberg, S Kalenic, E Könönen, B Lundgren, H Malamou-Ladas, E Nagy, A Sullivan, C E Nord.   

Abstract

Gram-positive anaerobic cocci (GPAC) are a heterogeneous group of microorganisms frequently isolated from local and systemic infections. In this study, the antimicrobial susceptibilities of clinical strains isolated in 10 European countries were investigated. After identification of 299 GPAC to species level, the minimum inhibitory concentrations of penicillin, imipenem, clindamycin, metronidazole, vancomycin and linezolid were determined by the agar dilution method according to the Clinical and Laboratory Standards Institute. The majority of isolates were identified as Finegoldia magna and Parvimonas micra (formerly Peptostreptococcus micros), isolated from skin and soft tissue infections. All isolates were susceptible to imipenem, metronidazole, vancomycin and linezolid. Twenty-one isolates (7%) were resistant to penicillin (n=13) and/or to clindamycin (n=12). Four isolates were resistant to both agents. The majority of resistant isolates were identified as F. magna and originated from blood, abscesses and soft tissue infections.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18180149     DOI: 10.1016/j.ijantimicag.2007.11.006

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  13 in total

1.  Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.

Authors:  Yangsoon Lee; Yongjung Park; Myung Sook Kim; Dongeun Yong; Seok Hoon Jeong; Kyungwon Lee; Yunsop Chong
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

2.  Antimicrobial susceptibility of clinically relevant Gram-positive anaerobic cocci collected over a three-year period in the Netherlands.

Authors:  A C M Veloo; G W Welling; J E Degener
Journal:  Antimicrob Agents Chemother       Date:  2010-12-28       Impact factor: 5.191

3.  Antimicrobial resistance surveillance systems: Are potential biases taken into account?

Authors:  Olivia Rempel; Johann Dd Pitout; Kevin B Laupland
Journal:  Can J Infect Dis Med Microbiol       Date:  2011       Impact factor: 2.471

4.  First human case of Fastidiosipila sanguinis infection.

Authors:  Clémence Beauruelle; Hervé Le Bars; Laurence Pougnet; Ludovic Lesecq; Philippe Buisson; Geneviève Héry-Arnaud
Journal:  J Clin Microbiol       Date:  2014-04-30       Impact factor: 5.948

5.  FAF and SufA: proteins of Finegoldia magna that modulate the antibacterial activity of histones.

Authors:  Elizabeth C Murphy; Tirthankar Mohanty; Inga-Maria Frick
Journal:  J Innate Immun       Date:  2013-12-11       Impact factor: 7.349

Review 6.  Anaerobic infections: update on treatment considerations.

Authors:  Elisabeth Nagy
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

7.  Five-year retrospective epidemiological survey of anaerobic bacteraemia in a university hospital and rewiew of the literature.

Authors:  E Urbán
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2012-06-13

8.  Evaluation of Antibiotic Susceptibility of Gram-Positive Anaerobic Cocci Isolated from Cancer Patients of the N. N. Blokhin Russian Cancer Research Center.

Authors:  Irina I Shilnikova; Natalia V Dmitrieva
Journal:  J Pathog       Date:  2015-12-21

9.  Identification of molecular mechanisms used by Finegoldia magna to penetrate and colonize human skin.

Authors:  Elizabeth C Murphy; Matthias Mörgelin; Dieter P Reinhardt; Anders I Olin; Lars Björck; Inga-Maria Frick
Journal:  Mol Microbiol       Date:  2014-09-11       Impact factor: 3.501

10.  Laboratory-based nationwide surveillance of antimicrobial resistance in Ghana.

Authors:  Japheth A Opintan; Mercy J Newman; Reuben E Arhin; Eric S Donkor; Martha Gyansa-Lutterodt; William Mills-Pappoe
Journal:  Infect Drug Resist       Date:  2015-11-18       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.